AzTrials
AzTrials

Alcohol Associated Liver DiseaseAddictoLIVENCT06472973

ADDICTOlogical Intervention in LIVEr Transplantation Recipients

A study testing Post-transplant addiction intervention in people with Alcohol Associated Liver Disease and Liver Transplantation, run by University Hospital, Montpellier at 16 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Transplantation for end-stage-liver disease (ESLD) in the context of Alcohol-Associated Liver Disease (AALD) has been increasing and represents the main indication for Liver Transplantation (LT) in the world. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Post-transplant addiction intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
720 participants
Where
16 sitesFrance
Study dates
21 Nov 2024to 21 Nov 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged 18 years or above
  • Hospitalized for LT for AALD as primary, secondary or tertiary indication
  • Discharged from intensive care unit to hepatology or surgery wards

Who cannot join

  • Severe alcohol-associated hepatitis as primary indication for liver transplantation
  • Impossibility of patient follow up over the next 2 years
  • General criteria:
  • Refusal or absence of informed consent,
  • Non-affiliation to the French national health insurance,
  • Persons placed under legal protection, guardianship or curatorship

Trial locations and contacts

16 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Hélène DONNADIEU, MD, PhD contact

0467337020 ext. +33

h-donnadieu@chu-montpellier.fr

16 sites in 1 country

France16 sites, 16 recruiting
  • Besançon University Hospital

    Besançon

    Claire VANLEMMENS

    Julie GIUSTINIANI

    Recruiting
  • Bordeaux University Hospital

    Bordeaux

    Faiza CHERMAK

    Recruiting
  • Clermont Ferrand University Hospital

    Clermont-Ferrand

    Armand ABERGEL

    Recruiting
  • Dijon University Hospital

    Dijon

    Marianne LATOURNERIE

    Recruiting
  • Lille University Hospital

    Lille

    Sebastien DHARANCY

    Recruiting
  • Lyon University Hospital

    Lyon

    Teresa ANTONINI

    Olivier LEJEUNE

    Recruiting
  • Marseille University Hospital

    Marseille

    Sophie CHOPINET

    Christophe LANCON

    Recruiting
  • Montpellier University Hospital

    Montpellier, 34000

    Hélène DONNADIEU

    Georges Philippe PAGEAUX

    Recruiting
  • Nice University Hospital

    Nice

    Rodolphe ANTY

    Régine TRUCHI

    Recruiting
  • APHP Mondor

    Paris

    Christophe DUVOUX

    Vincent LEROY

    Recruiting
  • APHP Paul Brousse

    Paris

    Audrey COILLY

    Lisa BLECHA

    Recruiting
  • APHP Salpetrière

    Paris

    Filomena CONTI

    An Hung NGUYEN

    Recruiting
  • Rennes University Hospital

    Rennes

    Pauline HOUSSEL

    Caroline LE LAN

    Recruiting
  • Strasbourg University Hospital

    Strasbourg

    Camille BESCH

    Anais LANG

    Recruiting
  • Toulouse University Hospital

    Toulouse

    Nassim KAMAR

    Recruiting
  • Tours University Hospital

    Tours

    Laure ELKRIEF

    Helene BARRAUD

    Recruiting

Other trials in France

About this study

Transplantation for end-stage-liver disease (ESLD) in the context of Alcohol-Associated Liver Disease (AALD) has been increasing and represents the main indication for Liver Transplantation (LT) in the world. Alcohol Use Disorder (AUD) is considered a brain chronic disease and requires a transdisciplinary approach that includes medical treatment and behavioral interventions.

In the context of LT, alcohol relapse occurs in 26 % up to 50% of LT recipients. Among Liver transplant recipients for AALD, severe alcoholic relapse (defined as more than 3 alcoholic drinks per day for women and 4/day for men) after LT leads to impaired longterm survival due to recurrent alcoholic cirrhosis (RAC), cardiovascular events and de novo cancer.

Read more

Several strategies have been developed to prevent alcohol relapse. After LT, integrating an addiction team into the LT program has been advocated by the latest guidelines in Europe and the United States, in order to bring the management of alcohol-use disorder (AUD) in transplantation units, through the association of psychosocial and pharmacological interventions previously reported in AALD. However, those guidelines were based on descriptive studies, and the effect of this management needs to be confirmed through a randomized, controlled, multicenter study, involving centers that still do not include an addiction team in their LT programs.

This study will therefore assess prospectively and comparatively the impact of an addiction intervention after LT on return to alcohol use rates. We hypothesize that standardized targeted addiction monitoring of Liver Transplant recipients decreases the rates of alcohol relapse two years post-liver transplantation.

Read the detailed description

Liver transplantation (LT) is the only curative option for end-stage liver disease and unresectable hepatocellular carcinoma (HCC) without extrahepatic spread. Alcohol Associated Liver Disease (AALD) has become the most common indication for liver transplantation (LT) in many Western countries.In France, AALD accounts for at least 40% of all LT, between decompensated cirrhosis and HCC, which represents more than 500 patients each year.

One, five and 10-year graft rate and patient survival rate after LT for AALD are at least comparable to those of other indications. Nevertheless, long-term survival rates are hampered by frequent and/or excessive relapse in alcohol consumption. Relapse increases the risk of recurrent alcohol-associated cirrhosis but also of de novo alcohol-induced solid malignancies, mainly cancers of the upper aero digestive tract. Graft and patient survival rates, especially long-term, are thus hindered by the occurrence of excessive relapse.

Relapse rates vary immensely between studies and there is a lack of standardization in the definition of its severity, mainly because it is impossible to define the boundaries/thresholds for "safe consumption". However, there is consensus that harm appears for alcohol intake exceeding three portions per day for males and two for females, for at least 100 days with a sense of loss of control. This pattern of relapse, often described as "severe" can be found between 10 and 26% of patients. Most efforts aiming to reduce post-LT relapse rates focus on improving patient selection. Risk-factors of alcohol relapse often found in literature include short duration of pre-LT sobriety (<6 months), diagnosis of alcohol dependence, family history of alcohol-use disorder, psychiatric comorbidities including other substance abuse, prior alcohol rehabilitation and female gender. Scores such as HRAR (High Risk Alcoholism Relapse) have also attempted to stratify relapse risk based on pre-LT risk factors. Unfortunately, these criteria are not sensitive enough and most patients who finally benefit from the intervention are in the low to medium risk groups.

It is therefore a priority to utilize also resources in the post-LT setting to decrease alcohol relapse since it is a frequent and relatively difficult to predict event, with a high impact on outcomes after LT. We hypothesize that post-transplant addiction specialist interventions in liver transplant patients with AALD as primary, secondary or tertiary indication will result in decreased regular and/or severe alcohol relapse rate two years post-LT. By extension, this could result in higher graft and patient survival rates, especially in long term.

More recently, our group has performed a retrospective analysis of three centers with different addiction follow-up practices suggesting a benefit on severe relapse rates of addiction specialist intervention after LT for AALD. However, the main limit of this work is the retrospective design with different follow-up periods and duration. We designed a multicenter superiority randomized controlled trial with 2 parallel arms:

  • Interventional arm where participants are offered targeted addictology follow-up and participate in addiction consultations
  • Control arm where participants have classical follow-up by the transplant specialists of the LT center during the post-transplant follow-up period

The randomization will be elaborated using 1:1 ratio and minimization method. It will be stratified on centers and alcohol consumption history.

According to a French cohort study of patients with liver transplantation for alcohol-related disorders, 25% of them relapsed at 2 years.To account for mortality censoring during follow-up, we will apply a 5% increase of the sample size to reach 720 participants (360 in each arm). The comparison of the primary endpoint between arms will be carried out using intention to treat principle. The time to relapse will be expressed using Kaplan-Meier curves in each arm, and compared using a log-rank test. The effect size will be estimated using Cox proportional.

Being tested
Post-transplant addiction intervention
Keywords
Liver transplantation, Addiction follow-up, Alcohol relapse, Survival

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Post-transplant addiction interventionOther

    The first addiction consultation will be conducted using the BRENDA method which allows the addiction specialist to carry out a psychosocial assessment, to entrust the results of this assessment to the participant, to answer their questions and to evaluate their reactions. Risk factors for alcohol relapse will be collected: social determinants, male gender, psychiatric comorbidities, duration of alcohol abstinence before LT(≥ or < 6 months) and young age (< 40 years). If the addiction specialist notes the presence of at least 3 risk factors for alcohol relapse, targeted addiction follow-up will be proposed to the participant including outpatient consultations with motivational interview at least every 4 weeks +/- pharmacological treatment of alcohol use disorder.In case of alcohol relapse or a period of high vulnerability to relapse, specific hospitalizations can be scheduled. If the participant has <3 risk factors, an addictology consultation every 6 months at most will be proposed.

Study groups in NCT06472973
Study groupRoleWhat they receive
Interventional groupExperimentalPatients randomized into the interventional arm will participate in an addiction consultation during their hospital stay following LT. The participant's addiction treatment will be based on the number of risk factors identified.
Receives: Other: Post-transplant addiction intervention
Control groupNo interventionParticipants randomized into the control arm will benefit from routine LT follow-up organized by the doctors and/or surgeons of the LT center during the post-transplant follow-up period. Usually, the patients have monthly outpatient visit with their physician during the first year after LT, then bi-monthly during the second year. At present, each center has a very different way of supporting transplant recipients, there is no systematic follow-up by an addictologist. Routine care at each center will be identified before the study set up. The different centers refer patients only after return to alcohol use is perceived in routine consultation or identified through biological alcohol markers. In this case, "the alcohol relapse" event will be noted and patients will be transferred to the addictologic center.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to return to alcohol use

    Time to return to alcohol use is defined by the time between discharge from Liver Transplantation (LT) hospitalization and alcohol relapse,it includes either:

    • Severe relapse: alcohol intake of at least 4 units per day for men and 3 per day for women for at least 100 days;
    • Regular relapse: no more than 21 units a week for men, 14 units a week for women, at least 10 times a month; Alcohol consumption will be collected using the alcohol timeline follow back (TLFB), the assessor will be blinded to the participant's arm allocation.

    TLFB is a calandar used to asses the participant's alcohol intake, it evaluates their daily drinking and provides a report of their drinking pattern over a given time period.

    The first TLFB assessment will be carried out one month after discharge from LT hospitalization, then every 2 months up to 2 years after discharge from LT hospitalization.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

Secondary outcomes (10)
  1. Return to alcohol use of the slip type

    Alcohol use will be measured using the TLFB,the assessor will be blinded to the participant's arm allocation.

    Slip type is defined by a unique excessive alcohol consumption (more than 4 alcohol drinks on a single occasion).

    The first TLFB assessment will be carried out one month after discharge from LT hospitalization, then every 2 months up to 2 years after discharge from LT hospitalization.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

  2. Tobacco use

    Tobacco use will be measured by relative reduction in the number of cigarettes smoked per day compared with baseline, and by smoking abstinence at 24 months after discharge from LT hospitalization, for at least one month. Tobacco use will be self reported by the participant during interviews with an assessor who is blinded to their arm allocation.

    Tobacco use assessment will be carried out one month after discharge from LT hospitalization, then every 2 months up to 2 years after discharge from LT hospitalization.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

  3. Other psychoactive substances use

    Psychoactive substances use (opiates, abuse drugs, psychostimulants or psychedelics ) will be self reported by the participant during interviews with an assessor who is blinded to their arm allocation.

    Psychoactive substances use assessment will be carried out one month after discharge from LT hospitalization, then every 2 months up to 2 years after discharge from LT hospitalization.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

  4. Addiction therapies

    Addiction therapies (behavioral, motivational therapy and medication) implemented in the intervention arm will be described.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

  5. Major significant clinical events

    Major significant clinical events includes death, cardiovascular events (myocardial infarction, pulmonary embolism, stroke), De Novo cancer and graft rejection.

    The occurrence of major significant clinical events will be collected during the participation period, time-to-event is defined as the time from LT until event or loss to follow-up or end of the study or death.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

  6. Biochemical liver tests

    Biochemical liver tests ( Alanine transaminase ALT, Aspartate transaminase AST, gamma-glutamyl transferase GGT, alkaline phosphatase and bilirubin) evolution will be assessed.

    Biochemical liver tests will be measured as X upper limit normal ULN, 3 months after discharge from LT hospitalization, then every 2 months up to 2 years after discharge from LT hospitalization.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

  7. Alcohol consumption biomarker ethanol/Peth)

    Alcohol use biomarker (Phosphatidylethanol/Peth) kinetics, tested 3 times a year, will be compared to self-reported alcohol consumption.

    Blood phosphatidylethanol concentration is determined by liquid chromatography coupled to a tandem mass spectrometer.

    Measured: At 1 month, 11 or 13 months and at 24 months after discharge from Liver transplantation hospitalization

  8. Liver fibrosis

    Liver fibrosis will be assessed using liver stiffness measurement by pulse elastometry (Fibroscan) and expressed in kilopascal (kPa).

    Measured: 2 years after discharge from Liver transplantation hospitalization

  9. Evolution of cognitive disorders

    Cognitive disorders will be measured using the Montreal Cognitive Assessment (MoCA) test which is a screening tool used to determine if there is any impairment in the participant's cognitive function, including their ability to understand, reason, and remember.

    The MoCA score ranges from 0 to 30:

    • 27-30: is considered normal
    • 18-26: indicates the presence of mild cognitive impairment
    • 10-17: indicates the presence of moderate cognitive impairment
    • < 10: indicates the presence of severe cognitive impairment

    MoCA test will be carried out at inclusion, 3 months after discharge from LT hospitalization then every 2 months up to 2 years after discharge from LT hospitalization.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

  10. Mortality and alcohol-associated mortality rate

    The occurrence of death (overall mortality and alcohol-associated mortality) will be collected during the participation period.

    Time-to-death is defined as the time from LT until death.

    Measured: During 2 years after discharge from Liver transplantation hospitalization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2024
  2. Study start21 Nov 2024
  3. Primary completion21 Nov 2028 (estimated)
  4. Study completion21 Nov 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
720 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06472973
Sponsor's protocol ID
RECHMPL23_0399
Other IDs
2023-A02801-44
Acronym
AddictoLIVE
Status last verified
Jun 2026
First submitted
18 Jun 2024
Last updated
22 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Post-transplant addiction intervention in people with Alcohol Associated Liver Disease and Liver Transplantation, run by University Hospital, Montpellier at 16 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hélène DONNADIEU, MD, PhD (0467337020 ext. +33, h-donnadieu@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to return to alcohol use (time frame: During 2 years after discharge from Liver transplantation hospitalization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in